DE602004031667D1 - Substituierte trialzole als blocker des natriumkanals - Google Patents

Substituierte trialzole als blocker des natriumkanals

Info

Publication number
DE602004031667D1
DE602004031667D1 DE602004031667T DE602004031667T DE602004031667D1 DE 602004031667 D1 DE602004031667 D1 DE 602004031667D1 DE 602004031667 T DE602004031667 T DE 602004031667T DE 602004031667 T DE602004031667 T DE 602004031667T DE 602004031667 D1 DE602004031667 D1 DE 602004031667D1
Authority
DE
Germany
Prior art keywords
pain
alone
pharmaceutically acceptable
effective amount
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004031667T
Other languages
German (de)
English (en)
Inventor
Min K Park
Prasun K Chakravarty
Bishan Zhou
Edward Gonzalez
Hyun Ok
Brenda Palucki
William H Parsons
Rosemary Sisco
Michael H Fisher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of DE602004031667D1 publication Critical patent/DE602004031667D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • AIDS & HIV (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
DE602004031667T 2003-11-10 2004-11-05 Substituierte trialzole als blocker des natriumkanals Expired - Lifetime DE602004031667D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51889003P 2003-11-10 2003-11-10
PCT/US2004/037280 WO2005047270A2 (en) 2003-11-10 2004-11-05 Substituted triazoles as sodium channel blockers

Publications (1)

Publication Number Publication Date
DE602004031667D1 true DE602004031667D1 (de) 2011-04-14

Family

ID=34590316

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004031667T Expired - Lifetime DE602004031667D1 (de) 2003-11-10 2004-11-05 Substituierte trialzole als blocker des natriumkanals

Country Status (17)

Country Link
US (2) US20090074890A1 (https=)
EP (1) EP1694654B1 (https=)
JP (1) JP2007510741A (https=)
KR (1) KR20060123739A (https=)
CN (1) CN1922156A (https=)
AT (1) ATE500234T1 (https=)
AU (1) AU2004289694B2 (https=)
BR (1) BRPI0416319A (https=)
CA (1) CA2545254A1 (https=)
DE (1) DE602004031667D1 (https=)
IL (1) IL175522A0 (https=)
IS (1) IS8438A (https=)
NO (1) NO20062676L (https=)
NZ (1) NZ547044A (https=)
RU (1) RU2372339C2 (https=)
WO (1) WO2005047270A2 (https=)
ZA (1) ZA200603583B (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY142651A (en) * 2003-03-18 2010-12-15 Merck Sharp & Dohme Biaryl substituted triazoles as sodium channel blockers
ATE500234T1 (de) * 2003-11-10 2011-03-15 Merck Sharp & Dohme Substituierte trialzole als blocker des natriumkanals
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
GB0603008D0 (en) * 2006-02-14 2006-03-29 Portela & Ca Sa Method
KR100808551B1 (ko) 2006-12-01 2008-03-03 한국생명공학연구원 트리아졸 유도체를 유효성분으로 함유하는 대사성 질환 예방 및 치료용 약학적 조성물
US8299107B2 (en) * 2007-02-08 2012-10-30 Synta Pharmaceuticals Corporation Triazole compounds that modulate HSP90 activity
WO2008124092A2 (en) * 2007-04-03 2008-10-16 E. I. Du Pont De Nemours And Company Substituted benzene fungicides
MX2010004549A (es) * 2007-10-25 2010-07-28 Revalesio Corp Composiciones y métodos bacteriostáticos o bactericidas.
EP2215260A4 (en) * 2007-10-25 2011-04-20 Revalesio Corp COMPOSITIONS AND METHOD FOR MODULATING CELL MEMBRANE-IMPROVED INTRA-CELLULAR SIGNAL TRANSMISSION
KR20100098653A (ko) 2007-11-21 2010-09-08 디코드 제네틱스 이에이치에프 염증의 치료를 위한 바이아릴 ｐｄｅ４ 억제제
CA2722582A1 (en) * 2007-11-21 2009-05-28 Decode Genetics Ehf. Biaryl pde4 inhibitors for treating inflammation
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
WO2011092290A1 (en) 2010-02-01 2011-08-04 Novartis Ag Pyrazolo[5,1b]oxazole derivatives as crf-1 receptor antagonists
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
EP2531490B1 (en) 2010-02-02 2014-10-15 Novartis AG Cyclohexyl amide derivatives as crf receptor antagonists
AR086554A1 (es) 2011-05-27 2014-01-08 Novartis Ag Derivados de la piperidina 3-espirociclica como agonistas de receptores de la ghrelina
JP2015525202A (ja) 2012-05-03 2015-09-03 ノバルティス アーゲー グレリン受容体アゴニストとしての２，７−ジアザ−スピロ［４，５］デカ−７−イル誘導体のｌ−リンゴ酸塩およびその結晶形態

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3682075B2 (ja) * 1993-04-16 2005-08-10 クミアイ化学工業株式会社 トリアゾール誘導体及び殺虫、殺ダニ剤
TW533205B (en) * 1996-06-25 2003-05-21 Novartis Ag Substituted 3,5-diphenyl-l,2,4-triazoles and their pharmaceutical composition
DE19816880A1 (de) * 1998-04-17 1999-10-21 Boehringer Ingelheim Pharma Neue Diphenyl-substituierte 5-Ring-Heterocyclen, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel
AR029489A1 (es) * 2000-03-10 2003-07-02 Euro Celtique Sa Piridinas, pirimidinas, pirazinas, triazinas sustituidas por arilo, composiciones farmaceuticas y el uso de las mismas para la manufactura de un medicamento
NZ520875A (en) * 2000-03-24 2005-04-29 Euro Celtique S Aryl substituted pyrazoles, triazoles and tetrazoles as sodium channel blocker
AR037233A1 (es) * 2001-09-07 2004-11-03 Euro Celtique Sa Piridinas aril sustituidas, composiciones farmaceuticas y el uso de dichos compuestos para la elaboracion de un medicamento
US20060183897A1 (en) * 2003-03-18 2006-08-17 Chakravarty Prasun K Biaryl substituted triazoles as sodium channel blockers
MY142651A (en) * 2003-03-18 2010-12-15 Merck Sharp & Dohme Biaryl substituted triazoles as sodium channel blockers
ATE500234T1 (de) * 2003-11-10 2011-03-15 Merck Sharp & Dohme Substituierte trialzole als blocker des natriumkanals

Also Published As

Publication number Publication date
ZA200603583B (en) 2007-08-29
US20090074890A1 (en) 2009-03-19
US7459475B2 (en) 2008-12-02
IS8438A (is) 2006-05-04
EP1694654B1 (en) 2011-03-02
EP1694654A2 (en) 2006-08-30
AU2004289694B2 (en) 2010-05-13
RU2372339C2 (ru) 2009-11-10
NZ547044A (en) 2010-05-28
WO2005047270A2 (en) 2005-05-26
AU2004289694A1 (en) 2005-05-26
CA2545254A1 (en) 2005-05-26
KR20060123739A (ko) 2006-12-04
ATE500234T1 (de) 2011-03-15
JP2007510741A (ja) 2007-04-26
BRPI0416319A (pt) 2007-01-09
RU2006120426A (ru) 2007-12-27
NO20062676L (no) 2006-08-10
WO2005047270A3 (en) 2005-09-22
CN1922156A (zh) 2007-02-28
US20060020006A1 (en) 2006-01-26
IL175522A0 (en) 2006-09-05

Similar Documents

Publication Publication Date Title
JO2480B1 (en) Triple aryl substituted with aryl as a sodium channel blocking agent
ATE500234T1 (de) Substituierte trialzole als blocker des natriumkanals
WO2004084824A3 (en) Biaryl substituted 6-membered heterocyles as sodium channel blockers
WO2007145922A3 (en) Benzazepinones as sodium channel blockers
DK0766672T3 (da) Arylsulfonamido-substituerede hydroxamsyrer som matrixmetallopreteinase-inhibitorer
MX2009004475A (es) Composiciones que comprenden agentes acido labiles que inhiben la bomba de protones, por lo menos otro agente farmaceuticamente activo y metodos de uso de las misma.
BR0308451A (pt) Composto, composição farmacêutica, métodos para o tratamento, prevenção ou melhoria de disfunção e método de fabricação de composto
BR0313352A (pt) Composto, composições farmacêuticas, método para a produção de um composto, método para o tratamento, prevenção ou a melhora de um distúrbio e método para o tratamento de um mamìfero
ATE536349T1 (de) In der 2-stellung durch phenyl substituierte 1h- benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren
WO2007075524A3 (en) Substituted piperidines as calcium channel blockers
MXPA05009611A (es) Piperidinas sustituidas como nuevos inhibidores de mdm2-p53.
WO2005030766A8 (en) Phenyl - carboxamide compounds useful for treating pain
IL185164A0 (en) New isothiazoloquinolones and related compounds as anti-infective agents
WO2004011477A3 (en) 6,11-4-carbon bridged ketolides
GEP20125389B (en) Substituted pyrazole and triazole compounds as ksp inhibitors
UA84879C2 (ru) Изотиазолохинолоны и родственные соединения с противомикробным действием
PH12022552495A1 (en) Oxazolidinone compound and methods of use thereof as an antibacterial agent
MXPA05013151A (es) 3-fluoro-piperidinas como antagonistas de n-metil-d-aspartato/nr2b.
GEP20257771B (en) Compounds and compositions as sppl2a inhibitors
WO2006009893A3 (en) Cancer chemotherapy
WO2024151638A3 (en) Compounds for fgfrs inhibitors
MX2024002892A (es) Azalidos inmunomoduladores.
MX2023009620A (es) Metodos terapeuticos.
TW200714596A (en) Isotopically substituted proton pump inhibitors
WO2025038882A3 (en) Method for treatment of seizures

Legal Events

Date Code Title Description
R081 Change of applicant/patentee

Ref document number: 1694654

Country of ref document: EP

Owner name: SCHERING CORPORATION, US

Free format text: FORMER OWNER: MERCK SHARP & DOHME CORP., RAHWAY, US

Effective date: 20121213

R082 Change of representative

Ref document number: 1694654

Country of ref document: EP

Representative=s name: ABITZ & PARTNER, DE

Effective date: 20121213